MET amplification results in heterogeneous responses to osimertinib in EGFR‐mutant lung cancer treated with erlotinib

Documenti analoghi

• Glycogen synthase kinase‐3 inhibition overcomes epithelial‐mesenchymal transition‐associated resistance to osimertinib in EGFR‐mutant lung cancer
  di: Fukuda, Koji, et al.
  Pubblicazione: (2020)
• Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case report
  di: Adachi, Yuta, et al.
  Pubblicazione: (2020)
• Triple Inhibition of EGFR, Met, and VEGF Suppresses Regrowth of HGF-Triggered, Erlotinib-Resistant Lung Cancer Harboring an EGFR Mutation
  di: Nakade, Junya, et al.
  Pubblicazione: (2014)
• Bronchoesophageal fistula formation after three courses of nivolumab for carcinoma of unknown primary with a subgroup of lung squamous cell carcinoma
  di: Nishiyama, Akihiro, et al.
  Pubblicazione: (2020)
• Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer
  di: Wang, Rong, et al.
  Pubblicazione: (2020)